SILO Key Statistics, Chart & Performance
The current stock price of SILO is 0.4405 USD. In the past month the price decreased by -10.93%. In the past year, price decreased by -51.14%.
SILO Latest News, Press Relases and Analysis
SILO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.96 | 400.12B | ||
| AMGN | AMGEN INC | 15.13 | 178.23B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.86B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.19 | 115.35B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.01 | 75.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 901.2 | 60.72B | ||
| INSM | INSMED INC | N/A | 43.84B | ||
| NTRA | NATERA INC | N/A | 33.50B | ||
| BIIB | BIOGEN INC | 10.89 | 26.74B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.5 | 21.02B | ||
| INCY | INCYTE CORP | 15.98 | 20.14B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.19B |
Related stock screener links
About SILO
Company Profile
Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. The company is headquartered in Sarasota, Florida. The company went IPO on 2012-01-05. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
Company Info
SILO PHARMA INC
677 N Washington Blvd
Sarasota FLORIDA US
Employees: 3
Phone: 17184009031
SILO PHARMA INC / SILO FAQ
What does SILO do?
Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. The company is headquartered in Sarasota, Florida. The company went IPO on 2012-01-05. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
Can you provide the latest stock price for SILO PHARMA INC?
The current stock price of SILO is 0.4405 USD. The price decreased by -2.44% in the last trading session.
What is the dividend status of SILO PHARMA INC?
SILO does not pay a dividend.
What is the ChartMill rating of SILO PHARMA INC stock?
SILO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the growth outlook for SILO PHARMA INC?
The Revenue of SILO PHARMA INC (SILO) is expected to decline by 0% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
SILO Technical Analysis
SILO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SILO. While SILO has a great health rating, there are worries on its profitability.
SILO Financial Highlights
Over the last trailing twelve months SILO reported a non-GAAP Earnings per Share(EPS) of -1.02. The EPS increased by 12.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -73.58% | ||
| ROE | -99.55% | ||
| Debt/Equity | 0 |